Fig. 4

Exogenous overexpression of miR-492 resisted the metapristone-induced antitumor effect in endometrial cancer. a The mRNA expression of miR-492 of RL95-2 cells and Ishikawa cells with ethanol or metapristone treatment (50 μM 48 h) were measured with real-time PCR. Values are means ± SD (n = 3 per group). b The mRNA expression of Klf5 and Nrf1 in RL95-2 cells and Ishikawa cells with or without metapristone and miR-492 + metapristone treatment (50 μM 48 h) were detected by real-time PCR. Non-treated and mir expression system cells were as control. Values are means ± SD (n = 3 per group). c Cell growth curves by MTT assay of RL95-2 cells and Ishikawa cells with or without metapristone and miR-492 + metapristone treatment (50 μM 48 h). Non-treated and mir expression system cells were as control. Results represent mean ± SD (n = 6 per group). d EdU assay was used to detect the cell proliferation phenotype with or without metapristone and miR-492 + metapristone treatment (50 μM 48 h) in RL95-2 cells and Ishikawa cells. Non-treated and mir expression system cells were as control. Results represent mean ± SD (n = 6 per group). e The protein expression of Cleaved-caspase 3 and Bax in RL95-2 cells and Ishikawa cells with or without metapristone and miR-492 + metapristone treatment (50 μM 48 h) were detected by western blot. Values are means ± SD. Non-treated and mir expression system cells were as control (n = 6 per group)